Immunotherapy offers hope for young women with rare Chemo-Resistant cancer

NCT ID NCT03135769

First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study tested a drug called avelumab in 24 women with a rare pregnancy-related cancer (GTN) that did not respond to standard chemotherapy. The goal was to see if the drug could lower their tumor marker (hCG) to normal levels. Avelumab works by helping the immune system attack the cancer cells, offering a potentially less toxic option for these young patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GESTATIONAL TROPHOBLASTIC NEOPLASIAS (GTN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aphp Hopital Tenon

    Paris, 75020, France

  • Centre Francois Baclesse

    Caen, 14000, France

  • Hospices Civils de Lyon - CHLS

    Pierre-Bénite, 69495, France

  • Institut Bergonie

    Bordeaux, 33000, France

  • Institut Paoli-Calmettes

    Marseille, 13000, France

  • Institut Universitaire Du Cancer de Toulouse - Oncopole

    Toulouse, 31000, France

Conditions

Explore the condition pages connected to this study.